紫元元(08223) - 2025 - 年度业绩

Financial Proceeds - The net proceeds from the subscription of new shares amounted to approximately HKD 43.5 million, fully allocated to the operational funding of the medical device and consumables trading business [3]. - All proceeds have been utilized within the fiscal year without significant changes or delays compared to the originally disclosed intentions [3].